Results 71 to 80 of about 6,976 (207)
, 2021 Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 KOREAN"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core
Infectious Diseases and Therapy, 2023 Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for outpatient treatment of mild-to-moderate COVID-19, significantly reducing the risk of ...
Julie M. Strizki +9 more
doaj +1 more source
Searching for Novel COVID19 Treatments: Towards Covalent TMPRSS2 Inhibitors
ChemMedChem, Volume 21, Issue 19, 14 October 2026.We designed, synthesised, and evaluated new guanidine derivatives as potential covalent inhibitors of TMPRSS2, a key protease for SARS‐CoV‐2 entry. Computational studies showed that some compounds have improved binding over nafamostat. However, experimentally none effectively blocked viral entry in cell assays, indicating further optimisation is needed.
Marco Minneci +6 more
wiley +1 more source
, 2021 Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 SPANISH"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and may
core
Биопрепараты: Профилактика, диагностика, лечение, 2022 Finding effective and safe medicines to fight SARS-CoV-2 infection is an urgent task. RPH-137 is an original trap fusion protein against SARS-CoV-2 virus.
E. V. Shipaeva +14 more
doaj +1 more source
, 2021 Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 SOMALI"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core
Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections [PDF]
, 2023 Importance: Ritonavir-boosted nirmatrelvir and molnupiravir are currently used in the US and in other countries to treat nonhospitalized patients who have mild-to-moderate COVID-19 and who are at high risk for progression to severe disease.
Lin, Dan-Yu +7 more
core +1 more source
Clinical and Translational Science, 2023 Molnupiravir is an orally administered, small‐molecule ribonucleoside prodrug of β‐D‐N4‐hydroxycytidine (NHC) that has demonstrated potent, broad‐spectrum preclinical activity against RNA viruses and has a high barrier to the development of resistance. A
Marian Iwamoto +10 more
doaj +1 more source
An Investigation of the Factors Reducing the Use of Hospital Services: A Systematic Review
Health Science Reports, Volume 9, Issue 10, October 2026.ABSTRACT Background and Aims Hospital service utilization has declined in many health systems due to policy shifts, limited resources, and alternative care approaches. This study aimed to systematically review the factors contributing to a reduction in the use or volume of hospital services.
Sedighe Sadat Tabatabaei Far +3 more
wiley +1 more source
Molnupiravir Inhibits Replication of Multiple Alphacoronavirus suis Strains in Feline Cells
PathogensThe cross-species spillover of coronaviruses is considered a serious public health risk. Feline coronavirus (FCoV), canine coronavirus (CCoV), and transmissible gastroenteritis virus (TGEV) are all classified under Alphacoronavirus suis and infect ...
Tomoyoshi Doki +3 more
doaj +1 more source